scholarly journals Role of probiotics in lower reproductive tract infection in women of age group 18 to 45 years

2017 ◽  
Vol 6 (2) ◽  
pp. 671
Author(s):  
Rukshana Shamshu ◽  
Jayasree Vaman ◽  
Nirmala C.
Keyword(s):  
Bacterial Vaginosis ◽  
Lactobacillus Reuteri ◽  
Lactobacillus Rhamnosus ◽  
Vulvovaginal Candidiasis ◽  
Controlled Study ◽  
Control Group ◽  
P Value ◽  
Double Blind ◽  
Reproductive Tract Infection ◽  
Conventional Antibiotics

Background: This study has been designed to assess the effectiveness of the probiotic strains having Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in the management of lower genital infections (bacterial vaginosis and candidiasis) as an integral therapy with antibiotics.Methods: Double blind, randomized placebo controlled study in women between 18-45 years attending Sree Avittom Thirunal Hospital (SATH), Government Medical College, Thiruvananthapuram, India with symptoms of bacterial vaginosis and vulvovaginal candidiasis. Women giving consent were given probiotics along with conventional antibiotics and were followed up over a period of two months. Outcome is measured as percentage of women showing a score of less than 4 at the end of thirty days of treatment, and sixty days of treatment in the test and control group in the case of bacterial vaginosis and no discharge and absence of hyphae and pseudohyphae in wet smear and gram stain in case of candidiasis.Results: Out of 42 women studied, 32 had bacterial vaginosis and 10 had vulvovaginal candidiasis. 81.3% women with BV had a normal vaginal picture after sixty days of treatment as compared to placebo which was only 31.3%. The p value is 0.004 which is significant. In the treatment of VC, the percentage of women cured was the same in both probiotic and placebo group.Conclusions: In the treatment of bacterial vaginosis, addition of probiotics to the conventional antibiotics can improve the cure rate of bacterial vaginosis and reduce the rate of recurrences. In the treatment of vulvovaginal candidiasis, addition of probiotics to the conventional antifungal did not have a significant improvement.

scholarly journals Effectiveness of Oral Probiotics (Lactobacillus Rhamnosus Gr1 and Lactobacillus Reuteri RC14) as Adjuvant Therapy in Reproductive Aged Women with Vaginal Discharge

2018 ◽  
pp. 3
Author(s):  
Junita Indarti ◽  
Utomo Budidarmo
Keyword(s):  
Sample Size ◽  
Vaginal Discharge ◽  
Lactobacillus Reuteri ◽  
Lactobacillus Rhamnosus ◽  
Control Group ◽  
P Value ◽  
Conditional Power ◽  
Satisfaction Level ◽  
Cure Rate ◽  
Double Blind

    Objective: To investigate the efficacy of oral probiotics andprove the high proportion of cure and satisfaction levels ofpost-treatment patients with a combination of antimicrobialprobioticoral Lactobacillus rhamnosus GR-1 and Lactobacillusreuteri RC-14 compared to a combination of antimicrobialplaceboin the treatment of reproductive aged patients withvaginal discharge in the outpatient obstetrics and gynecologicclinic in Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesiaand Arifin Achmad Regional Hospital Pekanbaru, Riau,Indonesia.   Methods: This was a randomized, double-blind, placebo-controlledtrial involving 50 subjects consisting of reproductive aged women.Data were collected using syndromic approach, probiotics weregiven as an adjuvant for standard antimicrobial therapy versusplacebo as control, response was recorded 4 weeks later, for cureproportion and satisfaction level. Statistical analysis was performedto assess the variables. Interim analysis with conditional powerassesment and futility testing were performed at midway due toinsufficient sample size. Research was approved by Ethics Commiteefor Health Researches Faculty of Medicine University of IndonesiaDr. Cipto Mangunkusumo Hospital in March 2016.   Results: A total of 50 subjects participated in this study andanalyzed (25 subjects in each group), cure proportion 56% (14) ofthe treatment and 60% (15) on the control group, with relativerisk of 1.1, Chi-square test p value 0.77 (95% CI; 0.57 to 2 , 11).High satisfaction level (score 67) was higher in the placebo(52.6%, 10 subjects) compared to probiotic group (47.4%,9 subjects), p value 0.65 (0.05). Conditional power and futilitytesting curve, revealed Z = -0.2865, conditional power 0.11 to0.13, and futility index of 0.87 to 0.88, equals to low possibility ofstatistical significance with full sample size (84).   Conclusion: There was no clinical and statistical difference in theproportion of cure rate and the level of satisfaction in patients ofprobiotics vs placebo groups after treatment for 4 weeks. Theinitial hypothesis of higher proportion of the cure rate in thetreatment group still cannot be excluded, due to insufficientsamples.   Keywords: bacterial vaginosis, lactobacillus reuteri RC-14, lactobacillusrhamnosus GR-1, randomized double blind controlled trial,trichomoniasis, vaginal discharge, vulvovaginal candidiasis

Improved cure of bacterial vaginosis with single dose of tinidazole (2 g),Lactobacillus rhamnosusGR-1, andLactobacillus reuteriRC-14: a randomized, double-blind, placebo-controlled trial

2009 ◽  
Vol 55 (2) ◽  
pp. 133-138 ◽  
Author(s):  
Rafael C. R. Martinez ◽  
Sílvio A. Franceschini ◽  
Maristela C. Patta ◽  
Silvana M. Quintana ◽  
Bruna C. Gomes ◽  
...  
Keyword(s):  
Single Dose ◽  
Placebo Group ◽  
Bacterial Vaginosis ◽  
Lactobacillus Reuteri ◽  
Controlled Trial ◽  
Lactobacillus Rhamnosus ◽  
Antimicrobial Treatment ◽  
Double Blind ◽  
Probiotic Group ◽  
Probiotic Lactobacilli

Bacterial vaginosis (BV) is the most prevalent vaginal infection worldwide and is characterized by depletion of the indigenous lactobacilli. Antimicrobial therapy is often ineffective. We hypothesized that probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 might provide an adjunct to antimicrobial treatment and improve cure rates. Sixty-four Brazilian women diagnosed with BV were randomly assigned to receive a single dose of tinidazole (2 g) supplemented with either 2 placebo capsules or 2 capsules containing L. rhamnosus GR-1 and L. reuteri RC-14 every morning for the following 4 weeks. At the end of treatment (day 28), the probiotic group had a significantly higher cure rate of BV (87.5%) than the placebo group (50.0%) (p = 0.001). In addition, according to the Gram-stain Nugent score, more women were assessed with “normal” vaginal microbiota in the probiotic group (75.0% vs. 34.4% in the placebo group; p = 0.011). This study shows that probiotic lactobacilli can provide benefits to women being treated with antibiotics for an infectious condition.

scholarly journals Effectiveness of Oral Probiotics as Adjuvant Therapy in Reproductive Aged Women with Vaginal Discharge

2018 ◽  
pp. 3
Author(s):  
Junita Indarti ◽  
Utomo Budidarmo
Keyword(s):  
Sample Size ◽  
Vaginal Discharge ◽  
Lactobacillus Reuteri ◽  
Controlled Trial ◽  
Lactobacillus Rhamnosus ◽  
P Value ◽  
Conditional Power ◽  
Satisfaction Level ◽  
Double Blind ◽  
Reproductive Aged Women

  Objective: To investigate the efficacy of oral proboiotics and prove the high proportion of cure and satisfaction levels of post-treatment patients with a combination of antimicrobial-probiotic oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 compared to a combination of antimicrobial-placebo in the treatment of reproductive aged patients with vaginal discharge in the outpatient obstetrics and gynecologic clinic in Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia and Arifin Achmad Regional Hospital Pekanbaru, Riau, Indonesia. Methods:This was a randomized, double-blind, placebo-controlled trial involving50 subjects consisting of reproductive aged women. Data were collected using syndromic approach, probiotics were given as an adjuvant for standard antimicrobial therapy versus placebo as control, response was recorded 4 weeks later, for cure proportion and satisfaction level. Statistical analysis was performed to assess the variables. Interim analysis with conditional power assesment and futility testing were performed at midway due to insufficient sample size. Research was approved by Ethics Commitee for Health Researches Faculty of Medicine University of Indonesia-Dr. Cipto Mangunkusumo Hospital in March 2016. Results: A total of 50 subjects participated in this study. and analyzed (25 subjects in each group), cure proportion 56%(14) of the treatment and 60%(15)on the control group, with relative risk of 1.1, Chi-square test p value (0.77, 95% CI; 0.57 to 2 , 11). High satisfaction level (score ≥67) was higher in the placebo (52,6%, 10 subjects) compared to probiotic group (47,4%, 9 subjects), p value 0,65 (≥0,05). Conditional power and futility testing curve, revealed Z = -0.2865, conditional power 0.11 to 0.13, and futility index of 0.87 to 0.88, equals to low possibility of statistical significance with full sample size (84). Conclusion: There was no clinical and statistical difference in the proportion of cure rate and the level of satisfaction in patients of probiotics vs placebo groups after treatment for 4 weeks. The initial hypothesis of higher proportion of the cure ratein the treatment group still cannot be excluded, due to insufficient samples. Keywords: bacterial vaginosis, , lactobacillus reuteri RC-14, lactobacillus rhamnosus GR-1, randomized double blind controlled trial, trichomoniasis , vaginal discharge,  vulvovaginal candidiasis.

scholarly journals Tranexamic acid for reducing blood loss following vaginal delivery: a double-blind randomized controlled trial.

2021 ◽  
Author(s):  
Francis Igboke ◽  
Lucky Lawani ◽  
Vitus Obi ◽  
Ikechukwu Dimejesi
Keyword(s):  
Treatment Group ◽  
Blood Loss ◽  
Tranexamic Acid ◽  
Vaginal Delivery ◽  
Controlled Trial ◽  
Controlled Study ◽  
Control Group ◽  
P Value ◽  
Double Blind ◽  
Estimated Blood Loss

Abstract Background: Postpartum haemorrhage (PPH) is a major cause of maternal morbidity and mortality worldwide with the highest incidence in the developing countries. Tranexamic acid (TXA) is a useful drug for prevention of PPH and merits evaluation in our environment. This study evaluates the efficacy of TXA in reducing blood loss following vaginal delivery.Methods: This was a double-blind randomized placebo-controlled study on the efficacy and safety of intravenous TXA in reducing blood loss in women undergoing vaginal delivery in a tertiary hospital. Data analysis was conducted with IBM SPSS software (version 20, Chicago II, USA). P-value <0.05 was considered statistically significant.Results: The mean estimated blood loss was lower in TXA compared with the placebo group (174.87±119.84 ml versus 341.07±67.97 ml respectively; P<0.0001). PPH (blood loss >500ml) was 5.13% in the study arm compared to the control arm 7.14%- risk ratio (RR) 0.82; 95% [CI 0.38 – 1.79, p=0.5956]. Additional uterotonics was required more in the control group compared to the treatment group 14(16.67%) versus 3(3.85%) of the treatment group, p-value of 0.007. There were no major complications noticed in the treatment group.Conclusion: This study demonstrated that intravenous administration of TXA acid following vaginal delivery reduced blood loss following vaginal delivery. It also reduced the need for additional uterotonics. However, blood loss greater than 500 was not significantly reduced.Pan African Clinical Trial Registry: PACTR202010828881019

scholarly journals Investigating the Effect of Quadruple Therapy with Saccharomyces Boulardii or Lactobacillus Reuteri Strain (DSMZ 17648) Supplements on Eradication of Helicobacter Pylori and Treatments҆ Side Effects: A Double-Blind Placebo-Controlled Randomized Clinical Trial

2021 ◽  
Author(s):  
Nooshin Naghibzadeh ◽  
Fatemeh Salmani ◽  
Samira Nomiri ◽  
Tahmine Tavakoli
Keyword(s):  
Helicobacter Pylori ◽  
Side Effects ◽  
Lactobacillus Reuteri ◽  
Eradication Therapy ◽  
Saccharomyces Boulardii ◽  
Controlled Study ◽  
Control Group ◽  
Double Blind ◽  
Quadruple Therapy ◽  
H Pylori

Abstract Background: The primary goal of this placebo-controlled study was to determine the effect of quadruple treatment with Saccharomyces boulardii or Lactobacillus reuteri on the eradication of Helicobacter pylori and side effects of the treatment.Results: This study was a double-blind, randomized, placebo-controlled trial. And, eradication of helicobacter pylori was reported comparing conventional anti-H. Pylori therapy versus conventional therapy supplemented with S. boulardii and L. reuteri DSMZ 17648. For this aim, a total of 156 patients were included in the current study; and patients positive for H. Pylori infection (n =156) were randomly assigned to 3 groups: 52 patients (Group P) received conventional quadruple therapy plus L. reuteri, 52 patients (Group S) received conventional quadruple therapy plus S. boulardii daily, for 2 weeks, and 52 patients were in the control group (Group C). At the end of the treatment period, all the subjects continued to take proton pump inhibitor (PPI) alone for 14 days, and then, no medication was given for 2 weeks again. During follow-up, gastrointestinal symptoms were assessed using an evaluation scale (Glasgow dyspepsia questionnaire (GDQ)), and adverse events were assessed at 7, 14, 21, and 28 days. As a result, eradication therapy was effective for 94.2% of subjects in Group S, 92.3% of subjects in Group P, and 86.5% of subjects in the control group, with no differences between treatment arms. In Group S, the chance of developing symptoms of nausea (OR=2.74), diarrhea (OR=3.01), headache (OR=10.51), abdominal pain (OR=3.21), and anxiety (OR=3.58) was significantly lower than in the control group (p<0.05).Conclusion: In general, our findings revealed that the use of probiotic supplements containing S. boulardii or Lactobacillus reuteri (DSMZ 17648 strain) improved the eradication rate of H. Pylori infection, but it was not statistically significant. Therefore, it is recommended to conduct future research with a larger sample size to investigate the effect of S. boulardii supplementation on eradicating H. pylori infection and reducing treatment side effects.Trial registration: IRCT20200106046021N1, this trial was registered on Jan 14, 2020.

scholarly journals Postoperative Ileus after Stimulation with Probiotics before Ileostomy Closure

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 626
Author(s):  
Ángela Rodríguez-Padilla ◽  
Germán Morales-Martín ◽  
Rocío Pérez-Quintero ◽  
Juan Gómez-Salgado ◽  
Rafael Balongo-García ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Postoperative Ileus ◽  
Loop Ileostomy ◽  
Bowel Function ◽  
Ileostomy Closure ◽  
Controlled Study ◽  
Control Group ◽  
Double Blind ◽  
Colorectal Cancer Surgery ◽  
Stimulation Of

Loop ileostomy closure after colorectal surgery is often associated with Postoperative ileus, with an incidence between 13–20%. The aim of this study is to evaluate the efficacy and safety of preoperative stimulation of the efferent loop with probiotics prior to ileostomy closure in patients operated on for colorectal carcinoma. For this, a prospective, randomized, double-blind, controlled study is designed. All patients who underwent surgery for colorectal carcinoma with loop ileostomy were included. Randomized and divided into two groups, 34 cases and 35 controls were included in the study. Postoperative ileus, the need for nasogastric tube insertion, the time required to begin tolerating a diet, restoration of bowel function, and duration of hospital stay were evaluated. The incidence of Postoperative ileus was similar in both groups, 9/34 patients stimulated with probiotics and 10/35 in the control group (CG) with a p = 0.192. The comparative analysis showed a direct relationship between Postoperative ileus after oncological surgery and Postoperative ileus after reconstruction surgery, independently of stimulation. Postoperative ileus after closure ileostomy is independent of stimulation of the ileostomy with probiotics through the efferent loop. There seem to be a relationship between Postoperative ileus after reconstruction and the previous existence of Postoperative ileus after colorectal cancer surgery.

CHRONIC ASTHMA IN CHILDHOOD: DOUBLE-BLIND CONTROLLED STUDY OF TREATMENT WITH GAMMA-GLOBULIN

PEDIATRICS ◽  
1958 ◽  
Vol 21 (6) ◽  
pp. 980-993
Author(s):  
Rosalind S. Abernathy ◽  
Edward L. Strem ◽  
Robert A. Good
Keyword(s):  
Gamma Globulin ◽  
Normal Population ◽  
Physical Growth ◽  
Controlled Study ◽  
Control Group ◽  
Chronic Asthma ◽  
Blood Proteins ◽  
Double Blind ◽  
Chemical Determination ◽  
Complete Blood Counts

To evaluate the effect of injections of gamma-globulin upon the course of asthma, observations were made with 22 asthmatic children ranging in age from 1½ to 5½ years. They had suffered from asthma from 1 to 13 years and were selected as subjects because they had not made satisfactory improvement under allergic management over an average of 2.4 years. They were placed in two groups by random assignment, one of which received injections of gamma-globulin. Without knowledge of the treatment being given, one author examined each child at the time of each injection and one month after the last injection. Roentgenograms, vital capacity, complete blood counts and chemical determination of the blood proteins were performed at the initial and final visits. Fifteen of the twenty-two patients improved clinically, eight in the treatment group and seven in the control group. No significant differences between the groups were noted in the amount of asthma, physical growth, hemoglobin value or eosinophilia. The concentration of gamma-globulin in the serum increased in the treated patients. Nevertheless, there was no difference in the incidence of infection in the two groups and in both it was equal to that in a normal population. This double-blind controlled study offers no evidence to support the view that treatment with gamma-globulin has a beneficial effect on the course of chronic asthma in children.

Omega-3 as an adjunctive therapy of sertraline and venlafaxine substantially improves symptoms of major depressive disorder: A double-blind, placebo-controlled study

2021 ◽  
Vol 10 ◽  
Author(s):  
Mohammad Ahadifard Moghaddam ◽  
Malihe Farid ◽  
Mahboobeh Mehrabani Natanzi ◽  
Zohre Khodaii ◽  
Rahim Badrfam ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Symptoms ◽  
Depressive Disorder ◽  
Controlled Study ◽  
P Value ◽  
Omega 3 ◽  
Major Depressive ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
Severity Of Depression

Background: Due to the possible effect of omega-3 fatty acids on reducing depressive symptoms, in this study, we investigated these effects in combination with other antidepressants. Methods: The study was a double-blind clinical trial on 100 patients with major depressive disorder who were divided into four groups of 25 each and treated with 50 mg daily sertraline plus placebo, 50 mg daily sertraline plus two grams Omega 3 daily, 75 mg daily venlafaxine plus placebo, and 75 mg daily venlafaxine plus 2 g Omega 3 daily for 6 weeks. Results: The mean Hamilton depression rating score of sertraline and venlafaxine plus omega-3 after treatment were 4.42 and 4.23 respectively versus sertraline and venlafaxine plus placebo 14.4 and 14.2 respectively (P value=0.0001). Conclusion: Omega-3 enhanced the clinical function of sertraline and venlafaxine to reduce the severity of depression. Adding omega-3 to either sertraline or venlafaxine does not have a comparative advantage over each other in terms of the improvement of severity of depressive symptoms. Trial registration : number is IRCT20190302042885N1.

Sign in / Sign up

Export Citation Format

Share Document